Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00077493
Recruitment Status : Suspended (protocol development and Amended protocol revision)
First Posted : February 12, 2004
Last Update Posted : December 28, 2007
Sponsor:
Collaborator:
Cambridge Antibody Technology
Information provided by:
MedImmune LLC

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : October 2008
Estimated Study Completion Date : October 2008